Security
Legend Biotech Corporation American Depositary Shares · LEGN
LEGNNASDAQotherCurrentCIK 1801198Updated Oct 14, 2026
LEGN price & chart
Loading TradingView…
NASDAQ:LEGN on TradingView ↗About the company
With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.
In the news
Legend Biotech Corporation Announces Pricing of Public Offering ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossUSD | -296,800,000Source | -177,026,000Source | -518,254,000Source | -446,349,000Source |
| Additional Financial Items | ||||
| AdjustmentsForCurrentTaxOfPriorPeriodUSD | — | — | — | 0Source |
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableUSD | -5,700,000Source | 93,754,000Source | -98,980,000Source | 50,320,000Source |
| AdjustmentsForFinanceCostsUSD | 21,400,000Source | 21,615,000Source | 21,794,000Source | 10,796,000Source |
| AdjustmentsForFinanceIncomeUSD | 40,100,000Source | 61,204,000Source | 54,487,000Source | 8,182,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD | 168,800,000Source | -109,346,000Source | 28,224,000Source | 9,159,000Source |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesUSD | 0Source | 0Source | -976,000Source | -3,709,000Source |
| OtherAdjustmentsToReconcileProfitLossUSD | 1,300,000Source | — | — | — |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | 3,600,000Source | 4,018,000Source | 3,755,000Source | 2,596,000Source |
| PurchaseOfFinancialAssetsMeasuredAtFairValueThroughProfitOrLossClassifiedAsInvestingActivitiesUSD | 0Source | 149,249,000Source | — | — |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | 0Source | 0Source | 2,638,000Source | 1,348,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Total RevenueUSD | — | 627,241,000Source | 285,143,000Source | 117,005,000Source |
| Additional Financial Items | ||||
| AdministrativeExpenseUSD | 135,800,000Source | 136,783,000Source | 106,769,000Source | 80,631,000Source |
| AverageEffectiveTaxRatenumber | -0.05Source | -0.12Source | 0Source | -0Source |
| BasicEarningsLossPerShareUSD per share | -0.81Source | -0.48Source | -1.47Source | -1.4Source |
| DepreciationRightofuseAssetsUSD | 19,500,000Source | 10,728,000Source | 7,823,000Source | 5,743,000Source |
| DilutedEarningsLossPerShareUSD per share | -0.81Source | -0.48Source | -1.47Source | -1.4Source |
| EmployeeBenefitsExpenseUSD | 492,300,000Source | 391,630,000Source | — | — |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesUSD | 64,600,000Source | 68,941,000Source | 47,680,000Source | 34,338,000Source |
| ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsedUSD | 3,700,000Source | 3,502,000Source | 2,338,000Source | 1,132,000Source |
| FinanceCostsUSD | 21,400,000Source | 21,615,000Source | 21,794,000Source | 10,796,000Source |
| FinanceIncomeUSD | 40,100,000Source | 61,204,000Source | 54,487,000Source | 8,182,000Source |
| ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipmentIncludingRightofuseAssetsUSD | 1,000,000Source | 4,400,000Source | — | — |
| IncomeTaxExpenseContinuingOperationsUSD | 14,200,000Source | 18,893,000Source | -1,864,000Source | 625,000Source |
| InterestExpenseOnLeaseLiabilitiesUSD | 3,500,000Source | 1,770,000Source | 1,394,000Source | 527,000Source |
| OtherEmployeeExpenseUSD | 10,600,000Source | 9,946,000Source | — | — |
| OtherIncomeUSD | — | 63,710,000Source | 57,463,000Source | 10,704,000Source |
| ProfitLossAttributableToOwnersOfParentUSD | — | -177,026,000Source | -518,254,000Source | -446,349,000Source |
| ProfitLossBeforeTaxUSD | -282,600,000Source | -158,133,000Source | -520,118,000Source | -445,724,000Source |
| ProfitLossFromOperatingActivitiesUSD | -136,500,000Source | — | — | — |
| ResearchAndDevelopmentExpenseUSD | 414,700,000Source | 413,544,000Source | 382,218,000Source | 335,648,000Source |
| TaxRateEffectOfForeignTaxRatesnumber | — | — | -0.09Source | -0.03Source |
Filing attachments
d81029dex991.htm · 6-K · 2026-06-22
Exhibit 99.1 Legend Biotech Corporation Announces Pricing of Public Offering BRIDGEWATER, NJ - June 17, 2026 - Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares (“ADSs”), each representing two ordinary shares of the Company, at a public offering price of $29.35 per ADS. In addition, Legend Biotech has granted the underwriters a 30-…
Read attachment ↗